BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 17023229)

  • 1. Development of a pharmacokinetic/pharmacodynamic model for carvedilol to predict beta1-blockade in patients with congestive heart failure.
    Tenero DM; Henderson LS; Campanile AM; Baidoo CA; Boyle D
    Am J Cardiol; 2006 Oct; 98(7A):27L-31L. PubMed ID: 17023229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
    Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM
    Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.
    Packer M; Lukas MA; Tenero DM; Baidoo CA; Greenberg BH;
    Am J Cardiol; 2006 Oct; 98(7A):39L-45L. PubMed ID: 17023231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic properties of a new controlled-release formulation of carvedilol.
    Tenero DM; Henderson LS; Baidoo CA; Harter AH; Campanile AM; Danoff TM; Boyle D
    Am J Cardiol; 2006 Oct; 98(7A):5L-16L. PubMed ID: 17023227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failure.
    Greenberg BH; Mehra M; Teerlink JR; Ordronneau P; McCollum D; Gilbert EM
    Am J Cardiol; 2006 Oct; 98(7A):53L-59L. PubMed ID: 17023233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial.
    Udelson JE; Pressler SJ; Sackner-Bernstein J; Massaro J; Ordronneau P; Lukas MA; Hauptman PJ
    J Card Fail; 2009 Jun; 15(5):385-93. PubMed ID: 19477398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial.
    Zebrack JS; Munger M; Macgregor J; Lombardi WL; Stoddard GP; Gilbert EM
    Pharmacotherapy; 2009 Aug; 29(8):883-90. PubMed ID: 19637941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of CASPER: compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol IR in patients with heart failure.
    Hauptman PJ; Pressler SJ; Sackner-Bernstein J; Ordronneau P; Udelson JE;
    Am J Cardiol; 2006 Oct; 98(7A):60L-66L. PubMed ID: 17023234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of carvedilol controlled-release in cardiovascular disease.
    Fonarow GC
    Expert Rev Cardiovasc Ther; 2009 May; 7(5):483-98. PubMed ID: 19419256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled-release carvedilol in the treatment of essential hypertension.
    Weber MA; Sica DA; Tarka EA; Iyengar M; Fleck R; Bakris GL
    Am J Cardiol; 2006 Oct; 98(7A):32L-38L. PubMed ID: 17023230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of a novel controlled-release formulation of carvedilol: pharmacology and clinical aspects. Introduction.
    Sica DA
    Am J Cardiol; 2006 Oct; 98(7A):1L-4L. PubMed ID: 17023226
    [No Abstract]   [Full Text] [Related]  

  • 12. Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate.
    Othman AA; Tenero DM; Boyle DA; Eddington ND; Fossler MJ
    AAPS J; 2007 Jun; 9(2):E208-18. PubMed ID: 17614362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled-release carvedilol: a concluding perspective.
    Packer M
    Am J Cardiol; 2006 Oct; 98(7A):67L-69L. PubMed ID: 17023235
    [No Abstract]   [Full Text] [Related]  

  • 14. Carvedilol: use in chronic heart failure.
    Doughty RN; White HD
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):21-31. PubMed ID: 17187454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial).
    Di Lenarda A; Remme WJ; Charlesworth A; Cleland JG; Lutiger B; Metra M; Komajda M; Torp-Pedersen C; Scherhag A; Swedberg K; Poole-Wilson PA;
    Eur J Heart Fail; 2005 Jun; 7(4):640-9. PubMed ID: 15921806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is urethane-chloralose anaesthesia appropriate for pharmacokinetic-pharmacodynamic assessment? Studies with carvedilol.
    Bertera FM; Di Verniero CA; Mayer MA; Bramuglia GF; Taira CA; Höcht C
    J Pharmacol Toxicol Methods; 2009; 59(1):13-20. PubMed ID: 18973819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid titration of carvedilol in patients with congestive heart failure: a randomized trial of automated telemedicine versus frequent outpatient clinic visits.
    Spaeder J; Najjar SS; Gerstenblith G; Hefter G; Kern L; Palmer JG; Gottlieb SH; Kasper EK
    Am Heart J; 2006 Apr; 151(4):844.e1-10. PubMed ID: 16569544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of beta blockers in heart failure.
    Talbert RL
    Heart Fail Rev; 2004 Apr; 9(2):131-7. PubMed ID: 15516861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs.
    Beddies G; Fox PR; Papich MD; Kanikanti VR; Krebber R; Keene BW
    Am J Vet Res; 2008 Dec; 69(12):1659-63. PubMed ID: 19046015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of different pharmacodynamic models for pharmacokinetic-pharmacodynamic (PK-PD) modeling of carvedilol.
    Liu XY; Wang BJ; Yuan GY; Guo RC
    Yao Xue Xue Bao; 2009 Apr; 44(4):406-11. PubMed ID: 19545060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.